Skip to main content

Table 3 Illness perception (assessed by BIPQ) following omalizumab treatment at each time point (longitudinal population)

From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Component Baseline Change at 6 months from baseline P-value Change at 12 months from baseline P-value
Consequences 7.3 ± 1.9 −2.0 ± 2.4 < 0.0001 −2.2 ± 2.7 < 0.0001
Timeline 8.1 ± 2.4 −1.0 ± 2.5 < 0.0001 −0.3 ± 2.4 0.1938
Personal control 5.9 ± 2.0 0.7 ± 2.3 0.0005 0.9 ± 2.5 0.0003
Treatment control 7.2 ± 2.3 0.9 ± 2.6 0.0001 1.1 ± 2.5 < 0.0001
Identity 7.6 ± 1.7 −2.2 ± 2.5 < 0.0001 −2.0 ± 2.6 < 0.0001
Concern 7.4 ± 2.3 −1.6 ± 3.0 < 0.0001 − 1.7 ± 3.0 < 0.0001
Emotions 7.0 ± 2.6 −1.2 ± 2.8 < 0.0001 −1.1 ± 3.0 < 0.0001
Illness comprehensibility 7.1 ± 2.3 0.4 ± 2.3 0.0690 0.7 ± 2.4 0.0076
  1. Data presented as mean ± SD
  2. P < 0.05 is considered as statistically significant. P-value was calculated using Wilcoxon test
  3. BIPQ Brief Illness Perception Questionnaire